CD94/NKG2C expression and HCMV serology according to the HLA-E genotypes
HLA-E genotypes* . | HLA-ER; n = 25 . | HLA-ER HLA-EG; n = 29 . | HLA-EG; n = 10 . | P . |
|---|---|---|---|---|
| % NKG2C† | 1.97 ± 2.9 | 2.5 ± 4.8 | 0.6 ± 1.1 | |
| 0.4 (0.1-10.4) | 0.5 (0.1-22.3) | 0.2 (0.1-3.5) | .15§ | |
| HCMV‡ | ||||
| Negative | 11 (44.0%) | 16 (55.6%) | 6 (60.0%) | .6∥ |
| Positive | 14 (56.0%) | 13 (44.8%) | 4 (40.0%) |
HLA-E genotypes* . | HLA-ER; n = 25 . | HLA-ER HLA-EG; n = 29 . | HLA-EG; n = 10 . | P . |
|---|---|---|---|---|
| % NKG2C† | 1.97 ± 2.9 | 2.5 ± 4.8 | 0.6 ± 1.1 | |
| 0.4 (0.1-10.4) | 0.5 (0.1-22.3) | 0.2 (0.1-3.5) | .15§ | |
| HCMV‡ | ||||
| Negative | 11 (44.0%) | 16 (55.6%) | 6 (60.0%) | .6∥ |
| Positive | 14 (56.0%) | 13 (44.8%) | 4 (40.0%) |
HLA-E typing was carried out as described in “Subjects, materials, and methods”
NKG2C+ cells were defined by flow cytometry. Expressed as mean ± SD and median (range)
Donors were classified in 2 groups according to the detection of serum HCMV-specific IgG
Analysis according to the Kruskal-Wallis test
Analysis according to the χ2 test